 WATERTOWN, Mass., Oct. 13, 2021 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical company advancing targeted protein degradation TPD to deliver novel small molecule protein degrader medicines, today announced that the Company will be giving multiple presentations at the 4th Annual Targeted Protein Degradation Summit, taking place from October 26 - 29, 2021. A Keynote Plenary Session presentation will include safety, pharmacokinetic PK and pharmacodynamic PD data, including cytokines, from the Single Ascending Dose SAD portion of the KT-474 Phase 1 trial in healthy volunteers that has recently completed dose escalation. KT-474 is a potential first-in-class, orally bioavailable IRAK4 degrader being developed for the treatment of TLRIL-1R-driven immune-inflammatory diseases including hidradenitis suppurativa, atopic dermatitis, rheumatoid arthritis, and others. 